Piper Jaffray Companies Boosts Halozyme Therapeutics, Inc. (HALO) Price Target to $29.00
Halozyme Therapeutics, Inc. (NASDAQ:HALO) had its target price hoisted by equities researchers at Piper Jaffray Companies from $26.00 to $29.00 in a research report issued on Monday. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ target price indicates a potential upside of 66.00% from the company’s previous close.
A number of other analysts have also recently weighed in on HALO. Barclays PLC restated an “overweight” rating and set a $16.00 target price on shares of Halozyme Therapeutics in a report on Friday, June 23rd. BidaskClub upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 24th. Canaccord Genuity set a $16.00 target price on shares of Halozyme Therapeutics and gave the stock a “buy” rating in a report on Wednesday, July 26th. Jefferies Group LLC restated an “underperform” rating and set a $7.00 target price (up from $6.75) on shares of Halozyme Therapeutics in a report on Thursday, August 10th. Finally, Zacks Investment Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a report on Friday, August 11th. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $17.00.
Shares of Halozyme Therapeutics (NASDAQ HALO) traded up 4.533% on Monday, hitting $18.262. The company had a trading volume of 565,544 shares. Halozyme Therapeutics has a 12 month low of $8.18 and a 12 month high of $18.43. The company has a 50-day moving average of $15.58 and a 200 day moving average of $13.72. The stock’s market cap is $2.45 billion.
Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.02. The business had revenue of $33.80 million for the quarter, compared to the consensus estimate of $31.76 million. The company’s quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.21) earnings per share. Analysts anticipate that Halozyme Therapeutics will post ($0.13) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Piper Jaffray Companies Boosts Halozyme Therapeutics, Inc. (HALO) Price Target to $29.00” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/16/piper-jaffray-companies-boosts-halozyme-therapeutics-inc-halo-price-target-to-29-00.html.
A number of institutional investors have recently bought and sold shares of the stock. Paulson & CO. Inc. acquired a new position in Halozyme Therapeutics in the 2nd quarter worth approximately $1,424,000. Dynamic Technology Lab Private Ltd acquired a new position in Halozyme Therapeutics in the 2nd quarter worth approximately $171,000. Verition Fund Management LLC boosted its stake in Halozyme Therapeutics by 50.4% in the 2nd quarter. Verition Fund Management LLC now owns 20,499 shares of the biopharmaceutical company’s stock worth $263,000 after purchasing an additional 6,866 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Halozyme Therapeutics by 524.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,011,449 shares of the biopharmaceutical company’s stock worth $12,968,000 after purchasing an additional 849,545 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Halozyme Therapeutics in the 2nd quarter worth approximately $131,000. 85.06% of the stock is owned by hedge funds and other institutional investors.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.